Omega-3 fatty acids have gained attention for their potential role in supporting liver health, particularly in the context of non-alcoholic fatty liver disease (NAFLD), which affects up to 30% of UK adults. These essential polyunsaturated fats—primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—may help reduce hepatic fat accumulation and inflammation through various metabolic mechanisms. Whilst research suggests omega-3s can decrease liver fat content, current UK guidance emphasises lifestyle interventions as first-line treatment. This article examines the evidence for omega-3 fatty acids in liver health, recommended sources and dosages, potential side effects, and when to seek medical advice.

What Are Omega-3 Fatty Acids and How Do They Support Liver Function?

Omega-3 fatty acids are essential polyunsaturated fats that the body cannot synthesise independently, making dietary intake crucial. The three main types are alpha-linolenic acid (ALA), found in plant sources, and the marine-derived eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These fatty acids play vital roles in cellular membrane structure, inflammatory regulation, and metabolic processes throughout the body.

In the context of liver health, omega-3 fatty acids exert several beneficial mechanisms. Research suggests they may help reduce hepatic lipogenesis (fat production in the liver) whilst enhancing fatty acid oxidation (fat breakdown), in part through downregulation of sterol regulatory element-binding protein-1c (SREBP-1c) and upregulation of peroxisome proliferator-activated receptor-alpha (PPAR-α). This dual action can help prevent excessive fat accumulation in hepatocytes (liver cells), a hallmark of non-alcoholic fatty liver disease (NAFLD). Additionally, omega-3s possess anti-inflammatory properties by serving as precursors to specialised pro-resolving mediators, which help dampen chronic inflammation that can contribute to liver injury and fibrosis.

Omega-3 fatty acids may also influence insulin sensitivity and lipid metabolism, both of which are closely linked to liver health, though clinical evidence for insulin sensitivity improvements is mixed. They can modulate the production of very-low-density lipoproteins (VLDL) in the liver, potentially reducing triglyceride levels in both the bloodstream and hepatic tissue.

Whilst omega-3s show promise in supporting liver function, they should be viewed as part of a comprehensive approach to liver health that includes weight management, balanced nutrition, regular physical activity, and avoidance of excessive alcohol consumption. The evidence base continues to evolve, and omega-3 supplementation should complement, rather than replace, established lifestyle interventions.

Evidence for Omega-3 Fatty Acids in Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) affects approximately 20–30% of adults in the UK and represents a spectrum from simple steatosis (fat accumulation) to non-alcoholic steatohepatitis (NASH), which involves inflammation and potential progression to cirrhosis. Research into omega-3 fatty acids as a therapeutic intervention has yielded encouraging, though not entirely conclusive, results.

Several systematic reviews and meta-analyses, including Cochrane reviews, have examined omega-3 supplementation in NAFLD patients. These studies generally demonstrate that omega-3 fatty acids, particularly EPA and DHA, can reduce hepatic fat content as measured by imaging techniques such as magnetic resonance spectroscopy or controlled attenuation parameter (CAP). Reductions in liver fat have been reported in some trials, with improvements often correlating with doses of 2–4 grams daily over periods of 6–12 months.

However, the evidence regarding liver enzyme normalisation is more variable. Whilst some studies show reductions in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, others report minimal changes. The impact on liver histology—including inflammation, ballooning, and fibrosis—remains less certain, with limited long-term biopsy data available. There is no established evidence that omega-3 supplementation reverses advanced fibrosis or cirrhosis.

NICE guidance (NG49: Non-alcoholic fatty liver disease: assessment and management) does not currently recommend omega-3 supplementation as a specific treatment for NAFLD, emphasising instead weight loss (7–10% of body weight), dietary modification, and increased physical activity as first-line interventions. The European Association for the Study of the Liver (EASL), in collaboration with EASD and EASO, similarly notes that whilst omega-3s may have metabolic benefits, they should not replace proven lifestyle measures. Patients with NAFLD should be assessed for cardiovascular risk factors and metabolic syndrome components, as these frequently coexist and require integrated management.

Recommended Omega-3 Dosage and Food Sources for Liver Health

For general health maintenance, the UK Scientific Advisory Committee on Nutrition (SACN) recommends consuming at least two portions of fish per week, including one portion of oily fish (approximately 140 g). The population recommendation for long-chain omega-3 intake is approximately 450 mg of EPA and DHA combined per day on average. A single 140 g portion of oily fish typically provides around 1–3 grams of EPA and DHA, well above the daily average target. However, for individuals specifically targeting liver health concerns, higher intakes may be considered under medical supervision.

Clinical trials investigating omega-3s in fatty liver disease have typically used doses ranging from 2 to 4 grams of combined EPA and DHA daily. These therapeutic doses generally exceed what can be obtained through diet alone and usually require supplementation. It is important to note that there is no established evidence guaranteeing improvements in liver health at specific doses, and individual responses may vary considerably.

Dietary sources rich in omega-3 fatty acids include:

• Oily fish: Salmon, mackerel, sardines, herring, trout, and pilchards provide EPA and DHA. Note that tinned tuna is not classified as an oily fish in UK guidance.

• Plant sources: Flaxseeds, chia seeds, walnuts, and rapeseed oil contain ALA. Conversion of ALA to EPA is limited (typically less than 10%), and conversion to DHA is very low (less than 1%).

• Fortified foods: Some eggs, spreads, and dairy products are enriched with omega-3s.

• Supplements: Fish oil, krill oil, and algal oil (suitable for vegetarians and vegans) capsules provide concentrated doses.

UK dietary safety advice is important, particularly for pregnancy and fish consumption. The NHS and Food Standards Agency (FSA) advise that women who are pregnant, breastfeeding, or planning pregnancy should limit oily fish to no more than two portions per week and avoid certain fish high in mercury (shark, marlin, swordfish). Tinned tuna should be limited to no more than four medium-sized tins per week during pregnancy. Fish liver oil supplements (such as cod liver oil) should be avoided during pregnancy due to high vitamin A content, which may harm the developing baby.

When selecting supplements, look for products that specify EPA and DHA content rather than total fish oil weight. Quality assurance is important—choose supplements that meet UK/EU contaminant limits and, where possible, are independently tested for purity (for example, by organisations such as IFOS, USP, or NSF). The Marine Stewardship Council (MSC) certification indicates sustainable sourcing but does not attest to contaminant testing. Patients should be aware that achieving therapeutic doses through diet alone would require consuming substantial quantities of oily fish daily, which may not be practical or desirable for everyone.

Potential Side Effects and Interactions with Liver Medications

Omega-3 fatty acid supplements are generally well-tolerated, but patients should be aware of potential adverse effects, particularly at higher doses. Common side effects include gastrointestinal symptoms such as fishy aftertaste, belching, nausea, loose stools, and abdominal discomfort. Taking supplements with meals or using enteric-coated formulations may help minimise these effects.

At doses exceeding 3 grams daily, omega-3s may have antiplatelet effects, potentially increasing bleeding risk. This is particularly relevant for patients taking anticoagulants (warfarin, direct oral anticoagulants) or antiplatelet agents (aspirin, clopidogrel). Whilst clinically significant bleeding is uncommon, patients on these medications should consult their GP or specialist before starting high-dose omega-3 supplementation. Regular monitoring of international normalised ratio (INR) is advisable for those on warfarin, as omega-3s may enhance anticoagulant effects.

Omega-3 ethyl ester preparations (such as Omacor) can raise LDL-cholesterol in some patients. If omega-3 supplementation is used in individuals with dyslipidaemia or cardiovascular risk, lipid monitoring may be clinically indicated. Additionally, high-dose purified EPA prescription products (such as icosapent ethyl) have been associated with an increased risk of atrial fibrillation in clinical trials. Patients with a history of atrial fibrillation should discuss this risk with their healthcare provider before starting high-dose omega-3 therapy.

For individuals with liver disease, omega-3 supplements are generally considered to have low hepatotoxicity. However, small increases in transaminases have occasionally been reported in product safety information. Patients with advanced cirrhosis or those taking multiple medications should exercise caution and discuss any new supplement with the healthcare team managing their liver condition.

Potential drug interactions to consider include:

• Antihypertensive medications: Omega-3s may have modest blood pressure-lowering effects, potentially enhancing the action of antihypertensives.

• Orlistat: This weight-loss medication may reduce absorption of fat-soluble nutrients, including omega-3s.

Patients should inform all healthcare providers about omega-3 supplementation, particularly before surgical procedures. Rather than automatically discontinuing omega-3s, patients should inform their surgical and anaesthetic teams, who will advise whether stopping is necessary. Evidence for increased surgical bleeding with omega-3 supplements is limited, and guidance varies. Those with fish or shellfish allergies should opt for algal-derived omega-3 supplements and check product labels carefully for potential allergens.

If you experience any suspected side effects from omega-3 supplements, you can report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

When to Seek Medical Advice About Liver Health and Supplements

Whilst omega-3 fatty acids are available over-the-counter and generally considered safe, certain circumstances warrant professional medical evaluation before starting supplementation or if symptoms develop during use. Patients should not self-diagnose or self-treat suspected liver conditions, as proper assessment and monitoring are essential.

Seek GP consultation before starting omega-3 supplements if you:

• Have been diagnosed with any liver condition (NAFLD, NASH, hepatitis, cirrhosis)

• Take anticoagulant or antiplatelet medications

• Have a bleeding disorder or upcoming surgery planned

• Are pregnant, breastfeeding, or planning pregnancy

• Take multiple medications or have complex medical conditions

• Have previously experienced allergic reactions to fish or seafood

• Have a history of atrial fibrillation and are considering high-dose omega-3 therapy

Contact your GP promptly if you experience:

• Persistent abdominal pain, particularly in the right upper quadrant

• Unexplained fatigue, weakness, or loss of appetite

• Jaundice (yellowing of skin or eyes)

• Dark urine or pale stools

• Unexplained bruising or bleeding

• Swelling of the abdomen or ankles

Seek urgent same-day assessment if you develop new jaundice with systemic symptoms, suspected upper gastrointestinal bleeding (vomiting blood or passing black, tarry stools), acute confusion (which may indicate hepatic encephalopathy), or rapidly progressive ascites.

These symptoms may indicate liver dysfunction requiring investigation through blood tests (liver function tests, full blood count) and imaging (ultrasound). NICE recommends (NG49) that patients with suspected NAFLD undergo comprehensive metabolic assessment, including evaluation for diabetes, dyslipidaemia, and cardiovascular risk. Importantly, liver function tests alone can be normal even in advanced liver disease and should not be relied upon for staging.

For individuals with confirmed NAFLD, risk stratification should follow NICE NG49 guidance. In primary care, use the FIB-4 score or NAFLD Fibrosis Score to assess the risk of advanced fibrosis. If the score is indeterminate or suggests high risk, arrange an Enhanced Liver Fibrosis (ELF) test. Refer to hepatology if advanced fibrosis is suspected based on these thresholds. Periodic reassessment of fibrosis risk is recommended, rather than routine liver function tests at fixed intervals.

Patients should maintain realistic expectations—omega-3s are not a cure for liver disease and work best as part of a holistic approach including weight management, dietary modification, alcohol avoidance, and treatment of associated metabolic conditions. If liver disease progresses or symptoms develop despite supplementation and lifestyle changes, referral to a hepatologist is appropriate for specialist assessment and consideration of additional therapeutic options.

Frequently Asked Questions